August 26th 2025
Patients taking orforglipron achieved significant weight loss, hemoglobin A1c reduction, and cardiometabolic benefits in the phase 3 ATTAIN-2 study, supporting upcoming global regulatory submissions.
Final Thoughts on Identifying and Managing Patients with T1D
Panelists discuss how early identification of Type 1 diabetes through screening programs, combined with emerging therapies like teplizumab, offers new opportunities for intervention and improved patient outcomes in at-risk populations.
Patient Selection For Teplizumab and Infusion Process
Panelists discuss how patient selection for teplizumab therapy requires screening for specific autoantibodies and stages of Type 1 diabetes, followed by a standardized 14-day outpatient infusion protocol with careful monitoring for side effects.